• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

How does Vaccination Impact Viral Load and Duration of Illness in Those with Breakthrough SARS-CoV-2 Infection?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Thompson et al. (NEJM, 2021) compared infection rates, mean viral RNA loads, and symptoms and the duration of illness among partially vaccinated, fully vaccinated, and non-vaccinated individuals

METHODS:

  • Prospective cohort study
  • Participants
    • Health care personnel, first responders, and other essential and frontline workers
  • Exposures
    • mRNA-based COVID-19 vaccination status
  • Study design 
    • Participants completed weekly SARS-CoV-2 testing (between December 14, 2020, to April 10, 2021)
    • The formula for calculating vaccine effectiveness was 100%×(1−hazard ratio for SARS-CoV-2 infection in vaccinated vs. unvaccinated participants)
    • Adjustments were made for the propensity to be vaccinated, study site, occupation, and local viral circulation
  • Primary outcome
    • Time to RT-PCR–confirmed SARS-CoV-2 infection in vaccinated participants vs unvaccinated participants
  • Secondary outcomes
    • Viral RNA load
    • Frequency of febrile symptoms and duration of illness among participants with SARS-CoV-2 infection

RESULTS:

  • 3975 individuals
  • SARS-CoV-2 positive tests: 5% (204 participants)
    • Fully vaccinated (≥14 days after dose 2) participants: 5 cases
    • Partially vaccinated (≥14 days after dose 1 and <14 days after dose 2) participants: 11 cases
    • Unvaccinated participants: 156 cases
  • Adjusted vaccine effectiveness
    • Full vaccination: 91% (95% CI, 76 to 97)
    • Partial vaccination: and 81% (95% CI, 64 to 90)
  • Mean viral RNA load was significantly lower in partially or fully vaccinated participants with breakthrough infection vs unvaccinated
    • RNA Load: 40% lower (95% CI, 16 to 57)
  • The risk of febrile symptoms and duration of illness were also lower in the breakthrough vaccine group
    • Febrile illness: Relative risk 0.42 (95% CI, 0.18 to 0.98)
    • Duration of illness: 2.3 fewer days spent sick in bed (95% CI 0.8 to 3.7)

CONCLUSION:

  • mRNA-based COVID-19 vaccines are highly effective at preventing infection in real-world conditions
    • 91% with full vaccination
    • 81% with partial vaccination
  • Among individuals who experienced breakthrough infection, vaccination also reduced the viral RNA load, risk of febrile symptoms, and duration of illness

The authors state

If further data confirm that the administration of mRNA vaccines reduces the number of viral RNA particles and the duration of viral RNA detection, thereby blunting the infectivity of SARS-CoV-2, then the overall results support that mRNA vaccines not only are highly effective in preventing SARS-CoV-2 infection but also may mitigate the effects of breakthrough infections — a finding that is especially important to essential and frontline workers, given their potential to transmit the virus through frequent close contact with patients, coworkers, and the public

Learn More – Primary Sources:

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

AstraZeneca and Pfizer Side Effects and Efficacy: Real World Data from the UK
Vaccines in Pregnant and Lactating Women: Is Immune Response Similar to that of Non-Pregnant Patients?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site